A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment

BACKGROUND: Cetuximab, a monoclonal antibody targeting Epidermal Growth Factor Receptor (EGFR), is currently used in metastatic colorectal cancer (mCRC), but predictive factors for therapeutic response are lacking. Mutational status of KRAS and EGFR, and EGFR copy number are potential determinants o...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Gonçalves, Anthony, Esteyries, Séverine, Taylor-Smedra, Brynn, Lagarde, Arnaud, Ayadi, Mounay, Monges, Geneviève, Bertucci, François, Esterni, Benjamin, Delpero, Jean-Robert, Turrini, Olivier, Lelong, Bernard, Viens, Patrice, Borg, Jean-Paul, Birnbaum, Daniel, Olschwang, Sylviane, Viret, Frédéric
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2008
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2432064/
https://ncbi.nlm.nih.gov/pubmed/18544172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-8-169
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi